IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+22.57%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$329M
AUM Growth
+$61.1M
(+23%)
Cap. Flow
-$36.5M
Cap. Flow
% of AUM
-11.09%
Top 10 Holdings %
Top 10 Hldgs %
43.78%
Holding
155
New
31
Increased
13
Reduced
30
Closed
17
Top Buys
| 1 |
Celldex Therapeutics
CLDX
|
$21.4M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$15.7M |
| 3 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$9.46M |
| 4 |
Gossamer Bio
GOSS
|
$9.15M |
| 5 |
Black Diamond Therapeutics
BDTX
|
$7.49M |
Top Sells
| 1 |
BioXcel Therapeutics
BTAI
|
$22.5M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$21.5M |
| 3 |
argenx
ARGX
|
$14.4M |
| 4 |
Immunovant
IMVT
|
$13.6M |
| 5 |
MYOV
Myovant Sciences Ltd.
MYOV
|
$8.74M |
Sector Composition
| 1 | Healthcare | 96.18% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Delcath Systems
DCTH
$388M
| $964K | 0.08% |
+94,000
| New | +$964K |
|
52
Soleno Therapeutics
SLNO
$3.7B
| $748K | 0.06% |
+22,453
| New | +$748K |
|
|
DBVT
53
DBV Technologies
DBVT
$252M
| $723K | 0.06% |
16,473
-6,338
| -28% | -$278K |
|
54
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $720K | 0.06% |
28,274
-330,650
| -92% | -$8.42M |
|
55
InflaRx
IFRX
$106M
| $700K | 0.06% |
152,600
-110,000
| -42% | -$505K |
|
56
Puma Biotechnology
PBYI
$257M
| $573K | 0.05% |
54,901
| – | – |
|
|
MYOV
57
DELISTED
Myovant Sciences Ltd.
MYOV
| $536K | 0.04% |
25,999
-424,001
| -94% | -$8.74M |
|
|
SIOX
58
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $533K | 0.04% |
188,884
| – | – |
|
|
OBSV
59
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $486K | 0.04% |
82,573
| – | – |
|
60
Gilead Sciences
GILD
$140B
| $478K | 0.04% |
+6,218
| New | +$478K |
|
61
Adverum Biotechnologies
ADVM
$66.5M
| $477K | 0.04% |
+2,284
| New | +$477K |
|
|
BXRX
62
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
| $415K | 0.03% |
71
-54
| -43% | -$316K |
|
|
63
argenx
ARGX
$44.9B
| $394K | 0.03% |
1,750
-64,106
| -97% | -$14.4M |
|
64
Incyte
INCY
$16.7B
| $385K | 0.03% |
+3,700
| New | +$385K |
|
|
GNFT
65
Genfit
GNFT
$194M
| $353K | 0.03% |
+64,027
| New | +$353K |
|
|
ARNA
66
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $315K | 0.03% |
+5,000
| New | +$315K |
|
67
Tempest Therapeutics
TPST
$44.5M
| $238K | 0.02% |
+693
| New | +$238K |
|
68
Syndax Pharmaceuticals
SNDX
$1.39B
| $237K | 0.02% |
+16,000
| New | +$237K |
|
69
Biogen
BIIB
$20.5B
| $213K | 0.02% |
795
| – | – |
|
70
Legend Biotech
LEGN
$6.46B
| $213K | 0.02% |
+5,000
| New | +$213K |
|
|
ITCI
71
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $185K | 0.01% |
7,202
-241,800
| -97% | -$6.21M |
|
72
Ultragenyx Pharmaceutical
RARE
$3.01B
| $181K | 0.01% |
2,313
-11,939
| -84% | -$934K |
|
73
iShares Russell 2000 ETF
IWM
$67.4B
| $165K | 0.01% |
1,154
-14,000
| -92% | -$2M |
|
|
SRRA
74
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $118K | 0.01% |
+9,658
| New | +$118K |
|
75
AnaptysBio
ANAB
$590M
| $102K | 0.01% |
+4,581
| New | +$102K |
|